Metformin protects against vascular calcification through the selective degradation of Runx2 by the p62 autophagy receptor

Kanchan Phadwal,Eve Koo,Ross A. Jones,Rachael O. Forsythe,Keyi Tang,Qiyu Tang,Brendan M. Corcoran,Andrea Caporali,Vicky E. MacRae
DOI: https://doi.org/10.1002/jcp.30887
2022-09-29
Journal of Cellular Physiology
Abstract:Our study suggests that exploitation of metformin and its analogues may represent a novel therapeutic strategy for clinical intervention of vascular calcification through the induction of AMPK/Autophagy Related 3 (Atg3)‐dependent autophagy and the subsequent p62‐mediated autophagic degradation of Runx2, runt‐related transcription factor 2 (Runx2). Vascular calcification is associated with aging, type 2 diabetes, and atherosclerosis, and increases the risk of cardiovascular morbidity and mortality. It is an active, highly regulated process that resembles physiological bone formation. It has previously been established that pharmacological doses of metformin alleviate arterial calcification through adenosine monophosphate‐activated protein kinase (AMPK)‐activated autophagy, however the specific pathway remains elusive. In the present study we hypothesized that metformin protects against arterial calcification through the direct autophagic degradation of runt‐related transcription factor 2 (Runx2). Calcification was blunted in vascular smooth muscle cells (VSMCs) by metformin in a dose‐dependent manner (0.5−1.5 mM) compared to control cells (p
cell biology,physiology
What problem does this paper attempt to address?